<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01223664</url>
  </required_header>
  <id_info>
    <org_study_id>SYS-1012</org_study_id>
    <nct_id>NCT01223664</nct_id>
  </id_info>
  <brief_title>Allogenic Bone Marrow Stem Cells Transplantation in Patients With Liver Cirrhosis</brief_title>
  <official_title>The Efficacy of Allogenic Bone Marrow Stem Cells Transplantation in Patients With Liver Cirrhosis Resulting From Chronic Hepatitis B</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sun Yat-sen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sun Yat-sen University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to evaluate the therapeutic efficacy of allogenic bone marrow
      stem cells (BMSCs) transplantation in patients with liver cirrhosis. The evaluation of the
      efficacy includes the level of serum alanine aminotransferase (ALT), aspartate
      aminotransferase(AST), total bilirubin (TB),prothrombin time (PT), albumin (ALB),
      prealbumin(PA), precollagenⅢ(PCⅢ), collagenⅣ(Ⅳ-C), laminin(LN), hyaluronidase(HN), liver
      histological improvement before and 1 week to 1 year after transplantation. Child-Pugh scores
      and clinical symptoms were also observed simultaneously.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>October 2010</start_date>
  <completion_date type="Anticipated">November 2011</completion_date>
  <primary_completion_date type="Anticipated">November 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Liver Function</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Immunity</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Liver Cirrhosis</condition>
  <arm_group>
    <arm_group_label>Group A(conserved therapy )</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Thirty of the enrolled patients were assigned to Group A were received comprehensive treatment including antiviral drugs, lowering aminotransferase and jaundice medicine.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B (BMSC Transplantion)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Thirty of the enrolled patients were assigned to Group B to receive comprehensive treatment including antiviral drugs, lowering aminotransferase and jaundice medicine, as well as bone marrow stem cells transplantation</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Allogenic bone marrow stem cells transplantation</intervention_name>
    <description>30ml allogenic bone marrow stem cells were infused to patients using interventional method via portal vein or hepatic artery as well as conserved therapy</description>
    <arm_group_label>Group B (BMSC Transplantion)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Conserved therapy</intervention_name>
    <description>Oral or intravenous administration</description>
    <arm_group_label>Group A(conserved therapy )</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Aged 16~65 years.

          -  Serum HBsAg positive for over six months.

          -  Ultrasonographic evidences of cirrhosis

        Exclusion Criteria:

          -  History of moderate to severe hepatic encephalopathy or variceal bleeding during the
             last two months before enrolment.

          -  Prothrombin time is over 30s.

          -  Cirrhosis caused by other reasons except HBV infection.

          -  Severe problems in other vital organs(e.g.the heart,renal or lungs).

          -  Liver tumor on ultrasonography, CT or MRI examination.

          -  Pregnant or lactating women.

          -  Imaging evidences of vascular thromboses.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lin B Liang, MD/PHD</last_name>
    <role>Principal Investigator</role>
    <affiliation>SunYat-sen University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sun Yat-sen University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510630</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <link>
    <url>http://www.zssy.com.cn/</url>
    <description>The Third Affiliated Hospital of Sun Yat-sen University</description>
  </link>
  <verification_date>October 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 12, 2010</study_first_submitted>
  <study_first_submitted_qc>October 18, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 19, 2010</study_first_posted>
  <last_update_submitted>October 18, 2010</last_update_submitted>
  <last_update_submitted_qc>October 18, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 19, 2010</last_update_posted>
  <responsible_party>
    <name_title>Lin Bingliang</name_title>
    <organization>Third Affiliated Hospital, Sun Yat-sen University</organization>
  </responsible_party>
  <keyword>ABMSC</keyword>
  <keyword>Allogenic bone marrow mesenchymal stem cells</keyword>
  <keyword>Liver cirrhosis</keyword>
  <keyword>Transplantation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fibrosis</mesh_term>
    <mesh_term>Liver Cirrhosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

